Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0HT2X
|
|||
| Former ID |
DIB005594
|
|||
| Drug Name |
CNT0-1959
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Rheumatoid arthritis [ICD-11: FA20] | Phase 2 | [1] | |
| Company |
Janssen biotech
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Anti-Interleukin-23 Monoclonal Antibody Guselkumab Shows Significant Efficacy in Treatment of Moderate to Severe Plaque Psoriasis. Janssen Research & Development, LLC (Janssen). Mar 24, 2014. | |||
| REF 2 | Interleukin-23 in the pathogenesis and treatment of psoriasis. Skin Therapy Lett. 2015 Mar-Apr;20(2):1-4. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.